These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25120040)

  • 1. Non-small-cell lung cancer resectability: diagnostic value of PET/MR.
    Fraioli F; Screaton NJ; Janes SM; Win T; Menezes L; Kayani I; Syed R; Zaccagna F; O'Meara C; Barnes A; Bomanji JB; Punwani S; Groves AM
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):49-55. PubMed ID: 25120040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thoracic staging with
    Schaarschmidt BM; Grueneisen J; Metzenmacher M; Gomez B; Gauler T; Roesel C; Heusch P; Ruhlmann V; Umutlu L; Antoch G; Buchbender C
    Eur Radiol; 2017 Feb; 27(2):681-688. PubMed ID: 27180186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
    Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
    Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNM Staging of Non-Small Cell Lung Cancer: Comparison of PET/MR and PET/CT.
    Huellner MW; de Galiza Barbosa F; Husmann L; Pietsch CM; Mader CE; Burger IA; Stolzmann P; Delso G; Frauenfelder T; von Schulthess GK; Veit-Haibach P
    J Nucl Med; 2016 Jan; 57(1):21-6. PubMed ID: 26471696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardized visual reading of F18-FDG-PET in patients with non-small cell lung cancer scheduled for preoperative thoracic lymph node staging.
    Rogasch JM; Apostolova I; Steffen IG; Steinkrüger FL; Genseke P; Riedel S; Wertzel H; Achenbach HJ; Kalinski T; Schultz M; Schreiber J; Amthauer H; Furth C
    Eur J Radiol; 2016 Aug; 85(8):1345-50. PubMed ID: 27423672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thoracic staging of non-small-cell lung cancer using integrated (18)F-FDG PET/MR imaging: diagnostic value of different MR sequences.
    Schaarschmidt B; Buchbender C; Gomez B; Rubbert C; Hild F; Köhler J; Grueneisen J; Reis H; Ruhlmann V; Wetter A; Quick HH; Antoch G; Heusch P
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1257-67. PubMed ID: 25852011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
    Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
    J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Diagnostic Accuracy for TNM Stage Among Whole-Body MRI and Coregistered PET/MRI Using 1.5-T and 3-T MRI Systems and Integrated PET/CT for Non-Small Cell Lung Cancer.
    Ohno Y; Takeshi Y; Takenaka D; Koyama H; Aoyagi K; Yui M
    AJR Am J Roentgenol; 2020 Nov; 215(5):1191-1198. PubMed ID: 32960670
    [No Abstract]   [Full Text] [Related]  

  • 9. Performance Comparison Between
    Kishida Y; Seki S; Yoshikawa T; Itoh T; Maniwa Y; Nishimura Y; Ohno Y
    AJR Am J Roentgenol; 2018 Jul; 211(1):185-192. PubMed ID: 29667886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT.
    Ohno Y; Koyama H; Yoshikawa T; Nishio M; Aoyama N; Onishi Y; Takenaka D; Matsumoto S; Maniwa Y; Nishio W; Nishimura Y; Itoh T; Sugimura K
    Radiology; 2011 Nov; 261(2):605-15. PubMed ID: 21926377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
    Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
    Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
    Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
    Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small Cell Lung Cancer Staging: Prospective Comparison of Conventional Staging Tests, FDG PET/CT, Whole-Body MRI, and Coregistered FDG PET/MRI.
    Ohno Y; Yoshikawa T; Takenaka D; Koyama H; Aoyagi K; Yui M; Oshima Y; Hamabuchi N; Tanaka Y; Shigemura C; Oota S; Nomura M; Murayama K; Inui Y; Kikukawa K; Toyama H
    AJR Am J Roentgenol; 2022 May; 218(5):899-908. PubMed ID: 34877872
    [No Abstract]   [Full Text] [Related]  

  • 15. Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer.
    Nakamura H; Taguchi M; Kitamura H; Nishikawa J
    Gen Thorac Cardiovasc Surg; 2008 Aug; 56(8):404-9. PubMed ID: 18696206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observer variation in FDG PET-CT for staging of non-small-cell lung carcinoma.
    Hofman MS; Smeeton NC; Rankin SC; Nunan T; O'Doherty MJ
    Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):194-9. PubMed ID: 18828012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients.
    Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Seki S; Yui M; Yamagata H; Aoyagi K; Matsumoto S; Sugimura K
    Radiology; 2015 Jun; 275(3):849-61. PubMed ID: 25584709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.
    Li X; Zhang H; Xing L; Ma H; Xie P; Zhang L; Xu X; Yue J; Sun X; Hu X; Chen M; Xu W; Chen L; Yu J
    Radiother Oncol; 2012 Feb; 102(2):246-50. PubMed ID: 22100657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
    Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
    Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.